Meeting
2013 ASCO Annual Meeting
An open-label phase II study of ibrutinib in patients with refractory follicular lymphoma.
Authors
Gilles A. Salles
Centre Hospitalier Lyon Sud, Oullins, France
Gilles A. Salles , Ajay K. Gopal , Peter Martin , Robert Marcus , Georg Hess , Pier Luigi Zinzani , Tahamtan Ahmadi , Sen Hong Zhuang , Ronald Levy
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lymphoma and Plasma Cell Disorders
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Lymphoma
Clinical Trial Registration Number
NCT01779791
Citation
J Clin Oncol 31, 2013 (suppl; abstr TPS8614^)
DOI
10.1200/jco.2013.31.15_suppl.tps8614
Abstract #
TPS8614^
Poster Bd #
57C
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Open-label, dose-escalation, and expansion trial of CA-4948 in combination with ibrutinib in patients with relapsed or refractory hematologic malignancies.
First Author: Erel Joffe
Poster
2012 ASCO Annual Meeting
A multicenter phase II study of vorinostat in patients (pts) with relapsed or refractory indolent B-cell non-Hodgkin lymphoma (B-NHL) or mantle cell lymphoma (MCL).
First Author: Kiyoshi Ando
Poster
2018 ASCO Annual Meeting
The dual SYK/JAK inhibitor cerdulatinib demonstrates rapid tumor responses in a phase 2 study in patients with relapsed/refractory B- and T-cell non-Hodgkin lymphoma (NHL).
First Author: Paul A. Hamlin
Poster
2016 ASCO Annual Meeting
Long term toxicity and fatigue after treatment for non-Hodgkin lymphoma (NHL): An analysis of twelve collaborative lymphoma study Association (LYSA) trials, the Simonal Study.
First Author: Nicolas Mounier